MHRA accept Roche’s bladder cancer immunotherapy drug for Early Access to Medicines Scheme

Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from

Continue Reading

AstraZeneca expands their first line cancer immunotherapy programme

AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab

Continue Reading

Allergan increases pipeline with Parkinson’s deal

Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.

Continue Reading

Cancer Research UK reports immunotherapy drug that can extend life of cancer patients

A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with

Continue Reading

NHS England unveils investment in cancer services

Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines.   Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accelerator) machines, as part of a £130-million investment in radiotherapy

Continue Reading

Number of Prescribed Antibiotics Has Fallen for the First Time in England

Doctors in England have prescribed 2.2 million less antibiotics between 2014 to 2015. Data from Public Health England has shown a significant reduction of 40.7 million to 38.5. A report by the ‘English Surveillance Programme for Antimicrobial Utilisation and Resistance’ (ESPAUR) stated the 4.3 percent decline in antibiotic prescriptions has been noted to be the

Continue Reading

Lung function test used to diagnose COPD can aid patients whilst reducing healthcare costs

According to a recent study by the Canadian Medical Association Journal (CMAJ), patients with chronic obstructive pulmonary disease (COPD) would benefit greatly if pulmonary function testing was used more consistently when diagnosing the condition. COPD is currently the third principal cause of death worldwide and affects over 10% of adults. At the moment, testing airflow

Continue Reading

New EU study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients

Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy. An overview

Continue Reading